{"componentChunkName":"component---src-templates-topic-topic-tsx","path":"/topics/epilepsy/","result":{"data":{"firstChapter":{"id":"5b049e7f-5e24-5bcc-af53-ff98c396ad9e","slug":"summary","fullItemName":"Summary","subChapters":[],"depth":1,"htmlHeader":"<!-- begin field d51f734b-a96a-49c0-947d-2f72a77e4c48 --><h1>Epilepsy - Summary</h1><!-- end field d51f734b-a96a-49c0-947d-2f72a77e4c48 -->","htmlStringContent":"<!-- begin item 8e59d2d0-7e90-43d0-a441-8eb01ab7fddc --><!-- begin field e4bff544-d80b-4d8e-9901-dfd3afd8480f --><ul><li>A seizure<strong> </strong>is the transient occurrence of signs or symptoms due to abnormal excessive or synchronous neuronal activity in the brain.</li><li>Epilepsy is a disease of the brain defined by any of the following:<ul><li>At least two unprovoked seizures occurring more than 24 hours apart.</li><li>One unprovoked seizure and a probability of further seizures similar to the general recurrence risk after two unprovoked seizures, occurring over the next 10 years.</li><li>Diagnosis of an epilepsy syndrome.</li></ul></li><li>Convulsive status epilepticus is a prolonged convulsive seizure for 5 minutes or longer, or recurrent seizures one after the other without recovery in between.</li><li>A cause of epilepsy is only identified in about one third of people with the disorder. Causes include structural, genetic, infectious, metabolic, and immune.</li><li>In the UK, the prevalence of epilepsy is estimated to be 5–10 cases per 1000. It is more common in people with learning disabilities.</li><li>Clinical features of epilepsy are specific to the type of seizure and include:<ul><li>Short-lived (less than 1 minute), abrupt, generalised muscle stiffening with rapid recovery — suggestive of tonic seizure.</li><li>Generalised stiffening and subsequent rhythmic jerking of the limbs, urinary incontinence, tongue biting —suggestive of a generalised tonic-clonic seizure.</li><li>Behavioural arrest — indicative of absence seizure.</li><li>Sudden onset of loss of muscle tone — suggestive of atonic seizure.</li><li>Brief, 'shock-like' involuntary single or multiple jerks —suggestive of myoclonic seizure.</li></ul></li><li>Immediate management of a person having a seizure includes:<ul><li>Protecting the person from injury, checking their airway, and placing them in the recovery position after the seizure stops.</li><li>If a tonic-clonic seizure is prolonged or recurrent, emergency buccal midazolam may be given first-line in the community according to pre-arranged protocol.</li><li>Emergency admission to hospital if seizures do not respond promptly to treatment.</li></ul></li><li>All people suspected of having a first epileptic seizure should be urgently referred to a specialist for confirmation of the diagnosis.</li><li>All people with epilepsy should have a routine review at least once a year to assess:<ul><li>Seizure control, adverse effects and compliance with treatment, and appropriate antiepileptic drug prescribing.</li><li>The impact of epilepsy on work, education, and leisure activities, and how to manage risks.</li><li>Entitlement to drive.</li><li>Carers' skills in managing seizures.</li><li>Contraception needs and pregnancy planning information needs, if appropriate.</li></ul></li><li>Specialist advice should be sought for a person with confirmed epilepsy with:<ul><li>Poor seizure control or poorly tolerated treatment.</li><li>Previous prolonged or recurrent seizures, who have not been prescribed emergency treatment for use in the community, if appropriate.</li><li>Possible cognitive impairment.</li><li>A seizure-free history for the last 2 years, who would like to consider tapering or withdrawal from drug treatment.</li><li>Plans for pregnancy.</li></ul></li></ul><!-- end field e4bff544-d80b-4d8e-9901-dfd3afd8480f --><!-- end item 8e59d2d0-7e90-43d0-a441-8eb01ab7fddc -->","topic":{"id":"f8129267-de9a-585d-9e33-8725cd832f5f","topicId":"b393b08f-0928-43ec-abde-ec6b4844fdee","topicName":"Epilepsy","slug":"epilepsy","aliases":[],"chapters":[{"id":"5b049e7f-5e24-5bcc-af53-ff98c396ad9e","slug":"summary","fullItemName":"Summary","subChapters":[]},{"id":"6b88498d-4758-510e-afc3-ed87d1957cad","slug":"have-i-got-the-right-topic","fullItemName":"Have I got the right topic?","subChapters":[]},{"id":"e31fe7a4-1ae2-5cd9-b804-0d4c44e53ebc","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?","subChapters":[{"id":"7a679807-bda2-5ee7-9bde-7ecdc0762be8","slug":"changes","fullItemName":"Changes"},{"id":"7e16f4d4-24ca-5628-ba07-c486b95e90c5","slug":"update","fullItemName":"Update"}]},{"id":"535dff27-4aaa-57fa-80a1-d274bd3b4e59","slug":"goals-outcome-measures","fullItemName":"Goals and outcome measures","subChapters":[{"id":"48265493-8622-58e8-a018-48a3e42f1148","slug":"goals","fullItemName":"Goals"},{"id":"6c194eb8-ba43-5a68-a78f-51161a41e8db","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"c76ab727-494d-527d-a154-b8c28b77d8a4","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"6d0101cf-ff01-5958-a6fb-ebfbd77e76fd","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"d111772f-1391-5d7f-a517-24a28715a449","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"30ff44ac-b721-5577-a601-8c4d55fa848d","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"59735dcb-eba6-5d18-bea9-06c5d9c7b253","slug":"background-information","fullItemName":"Background information","subChapters":[{"id":"4966ce92-afe3-59eb-b304-caf674cc78ae","slug":"definition","fullItemName":"Definition"},{"id":"5bbc7943-77eb-54ab-a31a-50a8a32fb58b","slug":"causes","fullItemName":"Causes"},{"id":"2779c8f9-cdfd-5fc5-9a9e-ff78cc795095","slug":"prevalence","fullItemName":"Prevalence"},{"id":"d76a05be-28cf-51f2-9112-94a3089622ef","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"397d1dd0-2884-5fe1-93ec-86f60bb3f9b0","slug":"complications","fullItemName":"Complications"},{"id":"22457087-3e91-5c25-b650-d494bac54036","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"58d6be4c-1ac7-5b65-b78e-bff25e6e76e6","slug":"diagnosis","fullItemName":"Diagnosis","subChapters":[{"id":"9854a4d4-10b2-54cb-bde8-bd6851a2a8d3","slug":"assessment","fullItemName":"Assessment"},{"id":"e24eacf4-0b1d-5c8e-beb3-8e4373ee4f96","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"0b45afa2-7eab-5f3c-baa9-bf2274759bb7","slug":"management","fullItemName":"Management","subChapters":[{"id":"ac1322eb-1276-5dd0-bc64-f83fe4b15961","slug":"suspected-epilepsy","fullItemName":"Scenario: Suspected epilepsy"},{"id":"e72ec2fc-c602-5ac7-9d71-792f49a18f1f","slug":"managing-an-epileptic-seizure","fullItemName":"Scenario: Managing an epileptic seizure"},{"id":"f0726760-8fbd-5900-8525-9c2c98180d5a","slug":"routine-epilepsy-review","fullItemName":"Scenario: Routine epilepsy review"},{"id":"c14abfdb-dd66-5da7-90f4-aed8bb06d929","slug":"women-of-childbearing-age","fullItemName":"Scenario: Women of childbearing age"}]},{"id":"dc732fc8-8397-5b8b-886e-654a3d37dedf","slug":"prescribing-information","fullItemName":"Prescribing information","subChapters":[{"id":"a9cc1abe-202c-5ec3-9fa2-4bc1e9003e29","slug":"prescribing-antiepileptic-drugs","fullItemName":"Prescribing antiepileptic drugs"},{"id":"0a33c3f0-2ae8-515f-a2ce-2deeae71dba9","slug":"adverse-effects-of-antiepileptic-drugs","fullItemName":"Adverse effects of antiepileptic drugs"},{"id":"3b7a2ba0-89af-5839-8597-3c9290c9dc23","slug":"enzyme-inducing-antiepileptic-drugs","fullItemName":"Enzyme-inducing antiepileptic drugs"}]},{"id":"b4c758e3-f2ef-5920-8a4b-057ce3f83d8e","slug":"supporting-evidence","fullItemName":"Supporting evidence","subChapters":[]},{"id":"12d642de-145f-5602-a8e5-c6320aab1692","slug":"how-this-topic-was-developed","fullItemName":"How this topic was developed","subChapters":[{"id":"0cb744d0-8999-57a7-87e5-e25e4df6722a","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"0ad13cb3-2b8b-56c4-824c-8f777375a7bf","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"17531a22-0a95-5a68-a007-18cb5384f001","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"6b27fc25-7d42-5230-a79b-0c623eb6b606","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"7dd141fa-9fe8-54b2-b10c-584815f12e6f","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"4b23c7ea-9a6f-5491-aa41-741d7d52e107","slug":"references","fullItemName":"References","subChapters":[]}]}},"topic":{"id":"f8129267-de9a-585d-9e33-8725cd832f5f","topicId":"b393b08f-0928-43ec-abde-ec6b4844fdee","topicName":"Epilepsy","slug":"epilepsy","aliases":[],"topicSummary":"Epileptic seizure is a transient disturbance of consciousness, behaviour, emotion, motor function, or sensation, due to abnormal electrical activity","lastRevised":"Last revised in January 2021","nextPlannedReviewBy":"2024-07-01T00:00:00+01:00","nextPlannedReviewByDateTime":"2024-06","nextPlannedReviewByDisplay":"June 2024","specialities":[{"id":"e9e3ea2b-52b8-5242-bc9d-24052ea8647a","name":"Child health","slug":"child-health"},{"id":"08590215-7450-5fd4-bb09-b98865ce23ee","name":"Neurological","slug":"neurological"}],"chapters":[{"id":"5b049e7f-5e24-5bcc-af53-ff98c396ad9e","slug":"summary","fullItemName":"Summary","subChapters":[]},{"id":"6b88498d-4758-510e-afc3-ed87d1957cad","slug":"have-i-got-the-right-topic","fullItemName":"Have I got the right topic?","subChapters":[]},{"id":"e31fe7a4-1ae2-5cd9-b804-0d4c44e53ebc","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?","subChapters":[{"id":"7a679807-bda2-5ee7-9bde-7ecdc0762be8","slug":"changes","fullItemName":"Changes"},{"id":"7e16f4d4-24ca-5628-ba07-c486b95e90c5","slug":"update","fullItemName":"Update"}]},{"id":"535dff27-4aaa-57fa-80a1-d274bd3b4e59","slug":"goals-outcome-measures","fullItemName":"Goals and outcome measures","subChapters":[{"id":"48265493-8622-58e8-a018-48a3e42f1148","slug":"goals","fullItemName":"Goals"},{"id":"6c194eb8-ba43-5a68-a78f-51161a41e8db","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"c76ab727-494d-527d-a154-b8c28b77d8a4","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"6d0101cf-ff01-5958-a6fb-ebfbd77e76fd","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"d111772f-1391-5d7f-a517-24a28715a449","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"30ff44ac-b721-5577-a601-8c4d55fa848d","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"59735dcb-eba6-5d18-bea9-06c5d9c7b253","slug":"background-information","fullItemName":"Background information","subChapters":[{"id":"4966ce92-afe3-59eb-b304-caf674cc78ae","slug":"definition","fullItemName":"Definition"},{"id":"5bbc7943-77eb-54ab-a31a-50a8a32fb58b","slug":"causes","fullItemName":"Causes"},{"id":"2779c8f9-cdfd-5fc5-9a9e-ff78cc795095","slug":"prevalence","fullItemName":"Prevalence"},{"id":"d76a05be-28cf-51f2-9112-94a3089622ef","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"397d1dd0-2884-5fe1-93ec-86f60bb3f9b0","slug":"complications","fullItemName":"Complications"},{"id":"22457087-3e91-5c25-b650-d494bac54036","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"58d6be4c-1ac7-5b65-b78e-bff25e6e76e6","slug":"diagnosis","fullItemName":"Diagnosis","subChapters":[{"id":"9854a4d4-10b2-54cb-bde8-bd6851a2a8d3","slug":"assessment","fullItemName":"Assessment"},{"id":"e24eacf4-0b1d-5c8e-beb3-8e4373ee4f96","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"0b45afa2-7eab-5f3c-baa9-bf2274759bb7","slug":"management","fullItemName":"Management","subChapters":[{"id":"ac1322eb-1276-5dd0-bc64-f83fe4b15961","slug":"suspected-epilepsy","fullItemName":"Scenario: Suspected epilepsy"},{"id":"e72ec2fc-c602-5ac7-9d71-792f49a18f1f","slug":"managing-an-epileptic-seizure","fullItemName":"Scenario: Managing an epileptic seizure"},{"id":"f0726760-8fbd-5900-8525-9c2c98180d5a","slug":"routine-epilepsy-review","fullItemName":"Scenario: Routine epilepsy review"},{"id":"c14abfdb-dd66-5da7-90f4-aed8bb06d929","slug":"women-of-childbearing-age","fullItemName":"Scenario: Women of childbearing age"}]},{"id":"dc732fc8-8397-5b8b-886e-654a3d37dedf","slug":"prescribing-information","fullItemName":"Prescribing information","subChapters":[{"id":"a9cc1abe-202c-5ec3-9fa2-4bc1e9003e29","slug":"prescribing-antiepileptic-drugs","fullItemName":"Prescribing antiepileptic drugs"},{"id":"0a33c3f0-2ae8-515f-a2ce-2deeae71dba9","slug":"adverse-effects-of-antiepileptic-drugs","fullItemName":"Adverse effects of antiepileptic drugs"},{"id":"3b7a2ba0-89af-5839-8597-3c9290c9dc23","slug":"enzyme-inducing-antiepileptic-drugs","fullItemName":"Enzyme-inducing antiepileptic drugs"}]},{"id":"b4c758e3-f2ef-5920-8a4b-057ce3f83d8e","slug":"supporting-evidence","fullItemName":"Supporting evidence","subChapters":[]},{"id":"12d642de-145f-5602-a8e5-c6320aab1692","slug":"how-this-topic-was-developed","fullItemName":"How this topic was developed","subChapters":[{"id":"0cb744d0-8999-57a7-87e5-e25e4df6722a","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"0ad13cb3-2b8b-56c4-824c-8f777375a7bf","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"17531a22-0a95-5a68-a007-18cb5384f001","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"6b27fc25-7d42-5230-a79b-0c623eb6b606","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"7dd141fa-9fe8-54b2-b10c-584815f12e6f","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"4b23c7ea-9a6f-5491-aa41-741d7d52e107","slug":"references","fullItemName":"References","subChapters":[]}]}},"pageContext":{"id":"f8129267-de9a-585d-9e33-8725cd832f5f"}},"staticQueryHashes":["3666801979"]}